Oncology-focused digital well being firm Flatiron Well being introduced it entered right into a strategic partnership with Large Bio, an organization that helps most cancers sufferers discover and enroll in scientific trials.
Flatiron Well being is an oncology-focused well being expertise firm that gives a platform aimed toward optimizing the scientific trial course of, together with choosing trial websites and figuring out sufferers who’re eligible for trials. The corporate additionally supplies digital well being document providers and scientific determination assist instruments to suppliers.
Large Bio makes use of AI to determine most cancers sufferers eligible for scientific trials and join them and their docs to relevant trials.
Flatiron will use Large Bio’s database on a per-study foundation to seek out sufferers who aren’t enrolled in scientific trials however stay near a trial web site.
These sufferers will then be directed to considered one of Flatiron’s analysis websites, the place they are often introduced on as new sufferers and probably enrolled in a scientific trial using Flatiron’s proprietary expertise and consolidated affected person identification providers.
“Flatiron Well being is worked up to hitch forces with Large Bio, combining experience and assets to advance customized remedy choices for most cancers sufferers,” Michael Bierl, vice chairman of scientific analysis partnerships and basic supervisor Europe at Flatiron Well being, stated in an announcement.
“By leveraging Large Bio’s strong community and database, we will proceed to make the most of our cutting-edge instruments to empower websites to progress analysis, improve workflows and efficiencies, speed up scientific hint tempo whereas making certain various affected person populations have entry to life-changing remedies which may in any other case be out of attain.”
Arturo Loaiza-Bonilla, cofounder and chief medical officer at Large Bio, stated the corporate’s mission is to make entry to scientific trials patient-centric and assure the proper affected person is matched to the proper trial on the proper time, no matter the place they stay.
“By pairing our AI-driven platform and concierge providers with Flatiron Well being’s intensive analysis infrastructure, we may also help physicians and care groups expedite trial enrollment, cut back disparities in entry and enhance outcomes for extra sufferers,” Loaiza-Bonilla stated in an announcement.
THE LARGER TREND
In March, the College of Colorado Most cancers Heart (CU Most cancers Heart) and Flatiron Well being joined forces to make scientific trials extra productive by reducing the executive burden for researchers.
The partnership introduced Flatiron Medical Pipe to the CU Most cancers Heart and UCHealth, which allowed scientific trial knowledge to maneuver instantly from digital well being information to digital knowledge seize techniques. The expertise additionally transfers info instantly from the EHR to trial databases.
Flatiron Medical Pipe is an digital well being document to digital knowledge seize connector that captures and transfers trial knowledge.
That very same month, Flatiron collaborated with NRG Oncology, a scientific analysis consortium within the Nationwide Most cancers Institute’s Nationwide Medical Trials Community, to make use of Flatiron Medical Pipe in a multicenter NRG scientific trial.
In February, Flatiron partnered with Actual Sciences to extend scientific proof era for Actual Sciences’ molecular residual illness take a look at Oncodetect. The alliance makes use of Flatiron’s scientific analysis platform to judge a variety of strong tumor sorts.
The goal was to collect scientific proof in a real-world setting and disparate affected person populations through the use of neighborhood care settings which are usually underrepresented in scientific trials.
In January, DeepScribe partnered with Flatiron to carry DeepScribe’s AI documentation to clinicians who use Flatiron’s OncoEMR, a cloud-based digital medical document platform.
The alliance made DeepScribe the primary ambient AI resolution accomplice for Flatiron Well being.
Final 12 months, Flatiron collaborated with the Affiliation of Most cancers Care Facilities (ACCC) to promote entry to scientific trials in a neighborhood setting, increase scientific research effectivity and improve the gathering of study-related knowledge.
In 2022, Large Bio secured $9 million in financing. Revo Capital and Kenan Turnacioğlu led the spherical, with participation from DEG. The corporate used the funds to develop its operations globally, market itself and launch new merchandise.
